Dear Respiratory friends, today was published intresting review on Management of Bronchoectasis!
Read full text: http://erj.ersjournals.com/content/45/5/1446.full
Formerly regarded as a rare disease, bronchiectasis is now
increasingly recognised and a renewed interest in the condition
is stimulating drug development and clinical
research. Bronchiectasis represents the final common pathway of a number
of infectious,
genetic, autoimmune, developmental and allergic
disorders and is highly heterogeneous in its aetiology, impact and
prognosis.
The goals of therapy should be: to improve
airway mucus clearance through physiotherapy with or without adjunctive
therapies;
to suppress, eradicate and prevent airway bacterial
colonisation; to reduce airway inflammation; and to improve physical
functioning
and quality of life.
Fortunately, an increasing body of
evidence supports interventions in bronchiectasis. The field has
benefited greatly from
the introduction of evidence-based guidelines in
some European countries and randomised controlled trials have now
demonstrated
the benefit of long-term macrolide therapy, with
accumulating evidence for inhaled therapies, physiotherapy and pulmonary
rehabilitation.
